Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CSL889 for vaso-occlusive crisis in sickle cell disease
NL-OMON60815Phase 3Completed
- Sponsor
- CSL Behring
- Start
- Jul 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of hemopexin in sickle cell disease (SCD), sponsored by CSL Behring. Primary endpoints: Time to resolution of vaso-occlusive crisis, Treatment-emergent adverse events and 3 more. Started Jul 2025; status: completed.
02
Drugs
hemopexin
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NL-OMON60815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60815.